Clinical impact of PSMA PET/CT in primary prostate cancer compared to conventional nodal and distant staging: A retrospective single center study

This study was attempted to assess the effect of Gallium-68 [68^Ga] labeled prostate specific membrane antigen (PSMA) positron emission tomography (PET)/x-ray computed tomography (CT) compared with conventional imaging on staging and clinical management of men evaluated for primary prostate cancer (PCa). Researchers retrospectively analyzed men with newly diagnosed biopsy-proven PCa who had been staged with a conventional staging protocol including bone scintigraphy (BS) and additionally underwent [68^Ga]PSMA PET/CT. They assessed the effect of PET/CT on clinical management by the percentage of treatment category changes after PET/CT as determined in the multidisciplinary tumour board. A total of 64 men with intermediate and high-risk PCa were included in the study. In N and M staging, PSMA PET/CT can cause considerable changes, as well as in management in comparison with conventional staging. In staging primary PCa, data of this research support the replacement of BS and CT by PSMA PET/CT.